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We conducted a cross-sectional study of β-herpes-
viruses in febrile pediatric oncology patients (n = 30), with 
a reference group of febrile pediatric solid-organ transplant 
recipients (n = 9). One (3.3%) of 30 cancer patients and 
3 (33%) of 9 organ recipients were PCR positive for cyto-
megalovirus. Four (13%) of 30 cancer patients and 3 (33%) 
of 9 transplant recipients had human herpesvirus 6B (HHV-
6B) DNAemia, which was more common within 6 months of 
initiation of immune suppression (4 of 16 vs. 0 of 14 cancer 
patients; p = 0.050). HHV-6A and HHV-7 were not detected. 
No other cause was identiﬁ  ed in children with HHV-6B or 
cytomegalovirus DNAemia. One HHV-6B–positive cancer 
patient had febrile disease with concomitant hepatitis. Other 
HHV-6B–positive children had mild “viral” illnesses, as did 
a child with primary cytomegalovirus infection. Cytomega-
lovirus and HHV-6B should be included in the differential 
diagnosis of febrile disease in children with cancer.
M
uch remains to be learned about the pathogenic role 
of β-herpesviruses (cytomegalovirus [CMV], human 
herpesvirus 6 variants A and B [HHV-6A and HHV-6B], 
and human herpesvirus 7 [HHV-7]) in immune-compro-
mised children. Most persons are infected with CMV, 
HHV-6B, and HHV-7 during childhood; the age of acqui-
sition and clinical spectrum of HHV-6A have not been de-
ﬁ  ned. In immune-competent children, CMV is associated 
with heterophile-negative mononucleosis, HHV-6B with 
roseola infantum (exanthem subitum or sixth disease), and 
HHV-7 with a small percentage of clinically recognized 
cases of roseola. However, most primary infections with 
these viruses are either asymptomatic or involve a nonspe-
ciﬁ  c mild illness that can include fever, malaise, and abnor-
mal liver function or hepatosplenomegaly (1–4). After pri-
mary infection, these viruses establish life-long residency 
in the host, seldom causing disease unless the immune sys-
tem is weakened, as occurs after treatment for solid-organ 
and stem cell transplantation. In these patients, each of the 
β-herpesviruses can reactivate, manifesting as febrile and 
sometimes life-threatening illness including pneumonitis, 
encephalitis, bone marrow suppression, graft-versus-host 
disease, and organ rejection (5–7). In addition to having 
independent pathologic effects, β-herpesviruses may have 
additive or synergistic effects, as well as interactions with 
other infectious agents (e.g., fungal infections) (8,9).
Immune suppression caused by cancer treatment has 
many forms, often as pulses of cytotoxic agents that kill 
rapidly dividing cells, including lymphocytes. The risk for 
infections in pediatric cancer patients is well recognized, 
and much effort has been devoted to identifying and treat-
ing bacterial and fungal infections associated with fever 
and neutropenia (10–14). This effort usually involves hos-
pitalization for empiric administration of intravenous anti-
microbial drugs, even though most bacterial blood cultures 
remain negative; 40%–70% of such febrile episodes have 
no identiﬁ  able source (15,16). Some viral infections, such 
as those with herpes simplex or varicella zoster viruses, are 
associated with disease that can be serious and even fatal in 
pediatric oncology patients (17,18). Most episodes of fever 
are unexplained and assumed to be viral in nature (19).
Little attention has been paid to the possible contri-
bution of β-herpesviruses as a cause of febrile illness in 
children with cancer, despite recognition that these viruses 
cause disease after organ transplantation. In studies that 
preceded application of PCR, CMV detection was associ-
ated with fever and hepatitis in children with malignancy 
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(20,21). HHV-6 seroprevalence is similar in pediatric can-
cer patients and controls (22,23), but virus has been de-
tected less frequently in saliva of children with cancer than 
that of healthy controls (24). In children from the Czech 
Republic, Michalek et al. detected both primary and reac-
tivated HHV-6 and CMV infections during cytotoxic che-
motherapy by using serologic analysis and PCR (23,25). 
Some HHV-6 infections were associated with severe dis-
ease, including pneumonitis, bone marrow aplasia, and per-
sisting fever.
Because of the biologic plausibility of β-herpesvirus 
involvement in febrile illness in pediatric cancer patients 
and the paucity of PCR-era literature in this area, we con-
ducted a cross-sectional study of the activity of these virus-
es in pediatric cancer patients and other immune-compro-
mised children. The purpose of this study was to determine 
whether there is sufﬁ  cient viral activity in these populations 
to warrant in-depth study and clinical consideration.
Materials and Methods
Patients
The study was reviewed and approved by the Cleve-
land Clinic Institutional Review Board. Informed consent 
was obtained from a parent or guardian of each person <18 
years of age, or directly from persons >18 years of age; as-
sent was obtained from children 7–17 years of age. Patients 
were enrolled from August 2004 through April 2005. En-
rolled children were receiving treatment for a malignancy 
or were receiving immunosuppressive therapy after solid-
organ transplantation (SOT). Inclusion criteria were an 
age of newborn to 21 years and new onset of fever with an 
oral or rectal temperature >38°C or an axillary temperature 
>37.5°C. At enrollment, we collected a blood specimen 
and information on age, sex, underlying illness and diagno-
sis, acute symptoms accompanying fever, and details about 
immune suppression (chemotherapy regimen, radiation 
therapy, immune modulators, and steroids). Gastrointesti-
nal symptoms were deﬁ  ned as either vomiting or diarrhea. 
Clinical laboratory data collected included complete blood 
counts, renal and liver function test results, bacterial blood 
cultures, as well as results of testing conducted for evalua-
tion of fever, such as respiratory virus analysis, stool stud-
ies, chest radiographs, and computed tomography scans.
Specimens and Storage
Whole blood was collected in EDTA tubes and stored 
at 4°C until processed. A leukocyte pellet was collected 
from 1 mL of whole blood; 400 μL of plasma was pre-
served, 200 μL for PCR and 200 μL for serologic analy-
sis. Pelleted leukocytes were added to MagnaPure LC lysis 
buffer (Roche Diagnostics, Indianapolis, IN, USA) and 
stored at –20°C.
Virus Culture
CMV culture was conducted with pelleted leukocytes 
by using conventional MRC-5 cell shell vial cultures (Diag-
nostic Hybrids, Athens, OH, USA). Immune ﬂ  uorescence 
testing was conducted after 48 hours by using a monoclonal 
antibody directed against the CMV immediate early protein 
(Chemicon, Temecula, CA, USA). Shell vial cultures were 
obtained for the ﬁ  rst 11 patients enrolled; all cultures were 
negative. Because shell vial culture uses a large number of 
leukocytes and we were studying a neutropenic population, 
this procedure was discontinued to preserve cells for more 
sensitive PCR analysis (26). Puriﬁ  ed lymphocytes were 
cultured to detect HHV-6 or HHV-7 infections as described 
(27,28). Cytopathic effect was recognized as enlarged and 
refractile cells, with conﬁ  rmatory testing by PCR.
Polymerase Chain Reaction
Template DNA was extracted by using the Mag-
naPure automated extraction method (Roche Diagnostics) 
and eluted into 50 μL of buffer. A total of 5 μL of eluted 
DNA was used in each PCR. The PCRs contained DNA 
extracted from the equivalent of ≈20 μL of plasma, leu-
kocytes present in 100 μL of whole blood, and 20 μL of 
whole blood. For detection of CMV and HHV-6 variants 
A and B, the Artus CMV RG PCR ASR/Real Art/Qiagen 
RealArt CMV LC Assay and the RealArt/Qiagen HHV-6 
A/B LC Assay (QIAGEN, Hamburg, Germany) were 
used. A co-ampliﬁ  ed internal control was used to identify 
PCR inhibition. To differentiate between HHV-6 variants, 
the system uses the speciﬁ  c melting temperatures of the 
probes. Detection of HHV-7 was conducted by using pre-
viously described primers and hybridization probes (29). 
Real-time PCR was performed on a LightCycler system 
(Roche Diagnostics).
Serologic Analysis
CMV serologic analysis was performed by using the 
VIDAS CMV IgG Assay (bioMérieux, Durham, NC, USA) 
in an automated instrument, according to the manufactur-
er’s protocol. Analyses for HHV-6 (using HHV-6A–in-
fected cells) and HHV-7 were conducted by using conven-
tional indirect immunoﬂ  uorescence with commercial slides 
(Panbio Ltd, Columbia, MD, USA). Avidity of antibody to 
HHV-6 was tested as described by Ward et al. (30).
Statistical Analysis and Clinical Associations
The exact unconditional test was used to compare 
groups on viral activity (31). All tests were 2-tailed and 
performed at a signiﬁ  cance level of 0.05. Analyses were 
performed by using StatXact PROCs version 6.3 (Cytel 
Software Corp., Cambridge, MA, USA) and SAS version 
9.1 (SAS Institute Inc., Cary, NC, USA). Clinical associa-
tions with β-herpesvirus infection were based on symptoms 
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and concomitant laboratory ﬁ  ndings in patients who had no 
other identiﬁ  able cause for their febrile illness. 
Results
Patient Characteristics
Forty-one children were enrolled, from whom 39 eval-
uable specimens were available (Table 1). Thirty of the 39 
children had a malignancy (our primary interest) and 9 were 
organ transplant recipients who were included for com-
parison. All cancer patients were receiving active therapy, 
except for 1 child who was included in the study because 
she had been receiving chemotherapy for 2.5 years, which 
ended 3 months before study enrollment. Several patients 
had symptoms in addition to fever, mostly upper respira-
tory or gastrointestinal. A source of fever was identiﬁ  ed 
for 5 (17%) of 30 cancer patients and 2 (22%) of 9 organ 
transplant recipients. Two cancer patients had bacteremia 
(Escherichia coli, coagulase-negative staphylococci); no 
fungal infections were detected. Three cancer patients and 
2 organ transplant recipients had respiratory viral infec-
tions diagnosed by symptoms and positive direct ﬂ  uores-
cent antibody test results. Of the 39 children, levels of liver 
enzymes were obtained for 28 as part of routine care. Of 
these children, 6 had abnormal values; 2 of these 6 also had 
virus detected (HHV-6B in 1 patient and inﬂ  uenza A in the 
other). The other 4 patients with increased levels of liver 
enzymes had longstanding abnormalities; review of their 
records suggested that the abnormal results were caused by 
underlying disease in 1 liver transplant patient and chemo-
therapy in 3 cancer patients. Six patients have died since 
completion of our study, none from infectious causes.
Laboratory Results
Of the 11 specimens tested in the shell vial assay, none 
was positive for CMV. CMV DNA was detected by PCR in 
lymphocytes of 1 (3.3%) of 30 cancer patients and 3 (33%) 
of 9 organ transplant recipients (Table 2).
Lymphocyte cultures for HHV-6 and HHV-7 were 
obtained for 34 of the 39 children. Of these, 15 cultures 
showed cytopathic effects similar to those commonly re-
ported for HHV-6, but none of these were positive for 
HHV-6 by PCR. Cultured cells from 1 patient with leuke-
mia (study participant 19) were positive for HHV-6B by 
PCR, in the absence of a cytopathic effect. Four (13%) of 
30 cancer patients and 3 (33%) of 9 transplant recipients (p 
= 0.19) had HHV-6B DNAemia; HHV-6A was not detect-
ed. Viral loads ranged from 50 to 500,000 DNA copies/mL. 
Of 7 PCR-positive patients, 3 also showed positive results 
in peripheral blood mononuclear cells (PBMC) and whole 
blood specimens, 2 in only PBMC, and 1 only in a lym-
phocyte culture. Patient 40, a transplant recipient, had posi-
tive results in all specimens tested including PBMC, whole 
blood, and plasma, with the highest viral load (>5 × 105 
genomes/mL) in PBMC. These results are consistent with 
either severe acute infection or the child having germline 
integrated HHV-6B (32,33). PCR positivity was more 
common in children whose blood was collected within 6 
months of initiation of immune suppression compared with 
children sampled >6 months after initiation of immune sup-
pression (cancer patients: 4 of 16 vs. 0 of 14 after 6 months, 
p = 0.050; transplant recipients: 2 of 3 vs. 1 of 6, p = 0.26) 
(Figure). Solid-tumor patients were less likely to be posi-
tive for HHV-6B than either leukemic (1 of 20 vs. 3 of 9, 
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Table 1. Characteristics of febrile immune-suppressed children* 
Characteristic
Cancer
(n = 30) 
SOT 
(n = 9) 
Age, y; mean, median, range  6.1, 5.0,
0.4–17
11.8, 13.3, 
4.3–20.6
Sex 
 F  14 7
 M  16 2
Basis of immune suppression 
 Cancer  30  (77%)  –
  Solid  tumor  20 –
  Leukemia  9 –
  Lymphoma  1 –
  Solid-organ transplant  – 9 (23%) 
  Heart  – 5
  Lung  – 2
  Liver  – 2
Immune suppressants  29 9
 Cytotoxic  chemotherapy  28 –
 Radiation  6 –
  Chemotherapy and radiation  6 –
 Immune  modulators†  – 9
  Steroids (past 6 months)  14 7
Signs and symptoms 
 Ill  appearance  7 1
 Upper  respiratory  17 1
 Gastrointestinal  10 7
 Headache  3 3
 Rash  0 0
 Seizure  0 0
 Hepatitis  1 1
Blood products (past 6 months)‡  20 5
Laboratory parameters 
  Neutropenic (<500 cells/PL) 14 2
  Lymphopenic (<500 cells/PL) 13 4
Established source for fever 
 Bacteremia  2 0
  Positive respiratory DFA test  
 result§ 
32
*SOT, solid-organ transplantation; –, not applicable; DFA, direct 
fluorescence antigen. 
†Immune modulators included tacrolimus in 4, tacrolimus and azathioprine 
in 2, cyclosporine and mycophenolate mofetil in 2, sirolimus in 1, and 
tacrolimus, mycophenolate mofetil, antithymocyte globulin (rabbit), and 
corticosteroids in 1. 
‡Blood products recorded included packed erythrocytes or platelets. 
§Of the 5 patients with positive respiratory DFA test results, 2 were 
positive for parainfluenza 3, 2 for influenza A, and 1 for respiratory 
syncytial virus. RESEARCH
p = 0.046) or SOT patients (1 of 20 vs. 3 of 9, p = 0.046). 
Two of the HHV-6B-positive SOT patients had concurrent 
CMV DNAemia.
HHV-7 DNA was not detected in any patients. Lym-
phocyte cultures were not tested for HHV-7 by PCR be-
cause none of the plasma, whole blood, or leukocyte pellets 
were positive for the virus.
Possible Associations between 
β-Herpesvirus Activity and Disease
Patients who were positive for β-herpesviruses and 
those who were negative for these viruses did not differ 
in their average fever temperature (38.5°C vs. 38.6°C). In 
SOT recipients, the prevalence of HHV-6B and CMV and 
the spectrum of their associated illnesses were concordant 
with prior reports. Thus, we will focus on the cancer pa-
tients.
The only cancer patient with CMV DNAemia appeared 
to have primary CMV infection on the basis of negative 
results for immunoglobulin (Ig) G to CMV, negative bacte-
rial blood culture, and age (online Appendix Table, avail-
able from www.cdc.gov/EID/content/14/4/579-appT.htm). 
This patient was a 5.4-year-old child (study participant 29) 
with acute lymphoblastic leukemia (ALL) in remission; he 
had upper respiratory symptoms and fever but otherwise 
appeared well. He was treated with an antimicrobial drug 
(ceftriaxone) on an outpatient basis, but his blood culture 
was negative for bacteria and no other source for his fever 
and illness was found. This child began cancer chemother-
apy 36 months before the febrile event.
Four patients appeared to have reactivated HHV-6B 
infection on the basis of positive results for virus DNA, 
high-avidity IgG, and clinical symptoms. The ﬁ  rst patient 
(study participant 19) was a 2-year-old boy with ALL in 
remission for the ﬁ  rst time. In the second month of chemo-
therapy; he was hospitalized for fever and ill appearance, 
but he was not neutropenic or lymphopenic. He had marked 
hepatomegaly (≈10 cm below the right costal margin) and 
abnormal results in liver function tests. He was receiving 
ﬂ  uconazole for oral thrush, and his liver enzyme levels were 
mildly increased before the febrile illness. However, at ad-
mission he had an aspartate aminotransferase (AST) level 
of 2,356 U/L and an alanine aminotransferase (ALT) level 
of 2,410 U/L. HHV-6 and HHV-7 IgM and IgG titers were 
obtained (Specialty Laboratories, Valencia, CA, USA) as 
part of his ALL treatment protocol. His HHV-6 IgM titer 
was negative (<40), and his IgG titer was positive (320) and 
high-avidity antibodies were detected. Results for HHV-7 
IgM were negative, and those for IgG were weakly positive 
(titer 20). Other studies conducted by the primary medical 
team included tests for acute hepatitis and a CMV PCR; all 
results were negative. Four days later, his AST level was 
84 U/L and his ALT level was 314 U/L. On follow up 7 
days after admission, both values were near normal. The 
hepatitis was attributed to methotrexate, which was there-
fore withheld until the levels of liver enzymes returned to 
normal. On the basis of the positive culture for HHV-6B 
and hepatitis in the setting of febrile illness without other 
identiﬁ  ed infections, we suspect that reactivated HHV-6B 
infection caused the fever and exacerbated the hepatitis.
A 5-year-old girl with relapsed acute myeloid leuke-
mia (study participant 23) was intermittently febrile while 
hospitalized for 1 month during chemotherapy. She was 
treated with broad-spectrum antibacterial drugs and anti-
fungal drugs. At study enrollment on day 12 of hospital-
ization, she had an absolute neutrophil count of 0 and an 
absolute lymphocyte count of 560 cells/μL. Daily blood 
cultures and sporadic respiratory viral studies did not re-
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Table 2. Detection of ȕ-herpesviruses in cancer patients and solid-organ transplant recipients* 
Cancer patients, no. positive/no. tested (%) 
Characteristic  Leukemia (n = 9)  Solid tumor (n = 20) 
Transplant patients (n = 9),  
no. positive/no. tested (%) 
CMV PCR  
Whole blood  1/6 (17)  0/5  3/7 (43) 
PBMC  1/7 (14)  0/16  2/8 (25) 
Plasma 0/9  0/20  2/9  (22) 
All tests  1/9 (11)  0/20 (0)  3/9 (33) 
HHV-6 PCR 
Whole blood  2/6 (33)  0/5  2/7 (29) 
PBMC  1/7 (14)  1/16 (6)  3/8 (38) 
Plasma 0/9  0/19  1/9  (11) 
Lymphocyte culture  1/8 (13)  0/16  0/9 
All tests  3/9 (33)  1/20 (5)  3/9 (33) 
HHV-7 PCR 
Whole blood  0/6  0/5  0/7 
PBMC 0/7 0/16  0/8 
Plasma 0/9  0/20  0/9 
All tests  0/9  0/20  0/9 
*Data are not shown for study participant 23, a patient with lymphoma who did not have ȕ-herpesviruses detected in whole blood, PBMC, or plasma. CMV, 
cytomegalovirus; PBMC, peripheral blood mononuclear cells; HHV-6, human herpesvirus 6. β-Herpesviruses in Febrile Children with Cancer
veal a cause for her fever, but her whole blood and PBMC 
were positive for HHV-6B by PCR.
HHV-6B was detected in a 2-year-old girl with ALL in 
remission (study participant 25) and in a 22-month-old boy 
with stage 3 Wilms tumor (study participant 38). Both of 
these patients were lymphopenic and had nonspeciﬁ  c febrile 
illnesses; neither had other identiﬁ  ed sources of fever.
 We suspect primary CMV infection in 1 patient and 
reactivated HHV-6B infection in 4 cancer patients as likely 
causes of the febrile episodes. This conclusion is based on 
a combination of clinical data, positive PCR ﬁ  ndings, and 
lack of other identiﬁ  ed sources for fever.
Discussion
β-Herpesviruses are known pathogens in immunocom-
promised patients, but they have not been extensively stud-
ied in children with malignancies. In this study of children 
who had fever, signs of infection, and had samples taken at 
1 time point, we detected β-herpesviruses in 5 of 25 cancer 
patients who had no other source of fever identiﬁ  ed: 4 had 
HHV-6B DNA and 1 had CMV DNA detected by PCR. 
β-Herpesviruses were detected in 4 of 7 SOT patients who 
had no other source of fever identiﬁ  ed: 1 had HHV-6B, 1 
had CMV, and 2 had both virues (Figure). One of these 
children was ill and had a high fever and pleuritis with no 
other pathogens identiﬁ  ed. HHV-6A and HHV-7 were not 
detected in any of the cancer or SOT patients. In our study, 
frequencies of HHV-6B were similar in transplant recipi-
ents and cancer patients (3 of 9 vs. 4 of 30, p = 0.19).
HHV-6B was detected more frequently in children with 
leukemia and solid-organ transplants than in children with 
other cancers. This ﬁ  nding may be the result of similarities 
in the degree and type of immune suppression. Children 
with leukemia and SOT patients generally receive intense 
initial immune suppression followed by a constant lower 
level of suppression. In contrast, solid-tumor patients gen-
erally receive monthly immune-suppressive treatments and 
seldom have prolonged lymphopenia. HHV-6B DNAemia 
was more frequent in children sampled during the ﬁ  rst 6 
months of immune suppression when immune suppression 
is most intense, which is consistent with ﬁ  ndings for pe-
diatric bone marrow and solid-organ transplant recipients 
(34). Detection of HHV-6B early after initiation of therapy 
in patients with cancer (Figure) suggests that the presence 
of virus DNA may be related to intense immune suppres-
sion and not to random occurrence, which would not have 
clustered early in therapy.
Our observations of possible clinical associations with 
β-herpesvirus infection concur with those of Michalek et al. 
(23,25) of a cohort dating from 1993 to 1999. Our popula-
tion included 1 child with suspected HHV-6 disease and 
hepatitis, which has been seen in association with HHV-6 
activity after liver (35), renal (36), and stem cell transplan-
tation (37).
In contrast to laboratory detection for CMV, testing for 
HHV-6 and HHV-7 DNA is often conducted by using in-
house assays, which makes comparison across studies dif-
ﬁ  cult. We used an assay for detecting HHV-6 DNA that is 
commercially available in Europe. This test was concordant 
with our in-house assay in detecting previously character-
ized HHV-6 isolates (D. Kohn et al., unpub. data). In addi-
tion to standardization of molecular testing, various meth-
ods for detecting HHV-6 during febrile episodes should be 
evaluated because some investigators have suggested that 
viral isolation by culture may be more useful in correlating 
active infection with clinical disease (38). Furthermore, re-
verse transcription–PCR can distinguish active replication 
from latency (39,40).
Several limitations are inherent to our cross-sectional 
study design. First, capturing data at single time points 
limits the ability to assess the temporality of the virologic 
burden in relation to disease. Second, although we found 
HHV-6B positivity during febrile events in 18% of our 
population, we do not have data during periods without 
fever and therefore cannot be certain that viremia is spe-
ciﬁ  cally associated with disease. The studies by Michalek 
et al. also included treatment-phase blood specimens that 
were obtained only during febrile illness or other clinical 
events suggestive of viral infection (23,25). Thus, activity 
of HHV-6 and other lymphotropic viruses during nonfe-
brile periods in this patient population remains unknown. 
We studied a heterogeneous patient population that includ-
ed several types of cancer; the level of immune suppression 
varied widely. Finally, identiﬁ  cation of possible causes of 
febrile episodes was limited by the assays we performed 
and the tests ordered by the primary medical team. Thus, 
we cannot exclude other viral pathogens such as human 
metapneumovirus or Epstein-Barr virus for which no test-
ing was conducted.
Evidence for our suspected associations between 
HHV-6B and the febrile events includes 1) our use of 
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Figure. Temporal relationship between detection of β-herpesvirus 
(βHV) and onset of immune suppression. Time of collection of each 
study specimen is indicated relative to onset of immune suppression 
for cancer patients and solid-organ transplant recipients. HHV, 
human herpesvirus; CMV, cytomegalovirus.RESEARCH
relatively small volumes of blood in the PCR analyses, 
which reduces the chance of detecting sporadic latently 
infected lymphocytes; 2) the temporal association of de-
tection of HHV-6B with initiation of chemotherapy; and 
3) a lack of other identiﬁ  ed sources for the fever. With the 
exception of the transplant recipient with possible HHV-
6B germline integration, HHV-6B or CMV are plausible 
causes of the febrile episode in every instance in which 
they were detected.
Our study differs from prior studies in that we assayed 
for all 4 β-herpesviruses and considered the timing of viral 
activity relative to the onset of immune suppression. We 
included solid-organ transplant patients as a reference for 
cancer patients, and excluded stem cell transplant patients, 
a population in whom reactivation of CMV and HHV-6 has 
been studied. By enrolling children with a variety of malig-
nancies, we surveyed a diverse cancer population.
Although the number of patients we studied was small, 
CMV and HHV-6B are clearly active in pediatric cancer 
patients. The lack of other identiﬁ   ed agents coincident 
with fever suggests that these viruses may cause febrile ill-
ness in this population. Our observations, combined with 
those of Michalek et al. (23,25), suggest that HHV-6B and 
CMV should be included in the differential diagnoses of 
febrile disease in children with cancer. Further investiga-
tion in this patient population is needed to clarify the role 
of β-herpesviruses in these febrile illnesses.
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